07 · Financing & capital markets

Financing & capital markets

Erasca says 44% of 25 responded; it’s Phase 1 · No. 052 · · About 1 min read

Bookmarks need a Mind Club sign-in. How sign-in works

No therapeutics financing of $5M or more found and counted from the window. SELLAS’s $150M offering, counted on 11.19, is expected to close on 11.20.

CompanyItemWhy it is not counted today
SELLAS Life Sciences$150.0M public offering, priced 11.18Already counted in the 11.19 edition
MegaRoboAbout $200M round, as reportedLab automation, out of scope
Marker Therapeutics$16.2M CPRIT awardA grant; grants are excluded
VitriVax$87M Series C, dated 11.18Already counted in the 11.19 edition
Boltz$110M Series A, as reportedAI models sold as tools, out of scope

SELLAS pricing release (11.18) (opens another website in a new tab) Co; Renaissance Capital IPO news, read 11.20: no biotech IPO filed, set terms or priced in the window Press.

RED TEAM

GlobeNewswire’s search and the Business Wire newsroom did not load for our sweep, so a quiet day here may be a gap in coverage, not in the market. Analysis